In type 2 diabetes with CVD and kidney disease, empagliflozin reduced mortality and hospitalization

被引：0
|
作者：
Moist, Louise [1 ]
机构：
[1] Western Univ, London, ON, Canada
来源：
ANNALS OF INTERNAL MEDICINE | 2018年 / 168卷 / 10期
关键词：
COTRANSPORTER; 2; INHIBITORS; CARDIOVASCULAR OUTCOMES;
D O I：
10.7326/ACPJC-2018-168-10-052
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：JC52 / JC52
页数：1
相关论文
共 50 条
  • [1] Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
    Wanner, Christoph
    Inzucchi, Silvio E.
    Lachin, John M.
    Fitchett, David
    von Eynatten, Maximilian
    Mattheus, Michaela
    Johansen, Odd Erik
    Woerle, Hans J.
    Broedl, Uli C.
    Zinman, Bernard
    Aizenberg, D.
    Ulla, M.
    Waitman, J.
    De Loredo, L.
    Farias, J.
    Fideleff, H.
    Lagrutta, M.
    Maldonado, N.
    Colombo, H.
    Ferre Pacora, F.
    Wasserman, A.
    Maffei, L.
    Lehman, R.
    Selvanayagam, J.
    d'Emden, M.
    Fasching, P.
    Paulweber, B.
    Toplak, H.
    Luger, A.
    Drexel, H.
    Prager, R.
    Schnack, C.
    Schernthaner, G.
    Fliesser-Goerzer, E.
    Kaser, S.
    Scheen, A.
    Van Gaal, L.
    Hollanders, G.
    Kockaerts, Y.
    Capiau, L.
    Chachati, A.
    Persu, A.
    Hermans, M.
    Vantroyen, D.
    Vercammen, C.
    Van de Borne, P.
    Mathieu, C.
    Benhalima, K.
    Lienart, F.
    Mortelmans, J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (04): : 323 - 334
  • [2] Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
    Parving, Hans-Henrik
    Lambers-Heerspink, Hiddo
    de Zeeuw, Dick
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (18): : 1800 - 1801
  • [3] Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes Reply
    Wanner, Christoph
    Inzucchi, Silvio E.
    Zinman, Bernard
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (18): : 1801 - 1802
  • [4] In patients with type 2 diabetes and CVD, empagliflozin reduced incident or worsening nephropathy at 3.1 years
    Patel, Tejas
    [J]. ANNALS OF INTERNAL MEDICINE, 2016, 165 (08) : JC39 - JC39
  • [5] Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease
    Fitchett, David
    Inzucchi, Silvio E.
    Lachin, John M.
    Wanner, Christoph
    van de Borne, Philippe
    Mattheus, Michaela
    Johansen, Odd Erik
    Woerle, Hans J.
    Broedl, Uli C.
    George, Jyothis T.
    Zinman, Bernard
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (03) : 364 - 367
  • [6] In CKD, empagliflozin reduced kidney disease progression at a median 2 y, regardless of primary kidney disease type
    Hwang, Jin Ho
    Hsu, Chi-yuan
    [J]. ANNALS OF INTERNAL MEDICINE, 2024, 177 (04) : JC40 - JC40
  • [7] Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
    Leitner, H.
    [J]. JOURNAL FUR KARDIOLOGIE, 2016, 23 (1-2): : 54 - 54
  • [8] Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
    Leitner, H.
    [J]. AUSTRIAN JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, 2016, 9 (01): : 22 - 22
  • [9] Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
    Fischereder, Michael
    Schoenermarck, Ulf
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (11): : 1092 - 1093
  • [10] Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
    Zinman, Bernard
    Wanner, Christoph
    Lachin, John M.
    Fitchett, David
    Bluhmki, Erich
    Hantel, Stefan
    Mattheus, Michaela
    Devins, Theresa
    Johansen, Odd Erik
    Woerle, Hans J.
    Broedl, Uli C.
    Inzucchi, Silvio E.
    Aizenberg, D.
    Ulla, M.
    Waitman, J.
    De Loredo, L.
    Farias, J.
    Fideleff, H.
    Lagrutta, M.
    Maldonado, N.
    Colombo, H.
    Ferre Pacora, F.
    Wasserman, A.
    Maffei, L.
    Lehman, R.
    Selvanayagam, J.
    d'Emden, M.
    Fasching, P.
    Paulweber, B.
    Toplak, H.
    Luger, A.
    Drexel, H.
    Prager, R.
    Schnack, C.
    Schernthaner, G.
    Fliesser-Goerzer, E.
    Kaser, S.
    Scheen, A.
    Van Gaal, L.
    Hollanders, G.
    Kockaerts, Y.
    Capiau, L.
    Chachati, A.
    Persu, A.
    Hermans, M.
    Vantroyen, D.
    Vercammen, C.
    Van de Borne, P.
    Mathieu, C.
    Benhalima, K.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (22): : 2117 - 2128
12345